# A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Source: https://onco.cc/trials/nct04064060/  
OnCo record `nct04064060` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Luspatercept in myelodysplastic syndromes / neoplasms and myeloproliferative neoplasms, run by Celgene, now recruiting.

## Summary

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials is a phase 3 interventional study registered as NCT04064060 by Celgene, with 665 participants planned, started 2019-08-12 and due to reach its primary completion in 2028-05-12. Interventions recorded: Luspatercept.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04064060
- Phase: 3
- Setting: A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Sponsor: Celgene
- Enrolled: 665

## Sources

- ClinicalTrials.gov NCT04064060: https://clinicaltrials.gov/study/NCT04064060

## Connected records

- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Luspatercept](https://onco.cc/drugs/luspatercept/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04064060.json